FDA Drug Recalls

Recalls / Class II

Class IID-0353-2023

Product

Levothyroxine Sodium Tablets, USP 112 mcg, 90 tablets per bottle, Rx Only, Manufactured by Lloyd Inc., Shenandoah, IA, 51601, Distributed by: Alvogen Inc, Pine Brook, NJ 07058, NDC 47781-654-90.

Brand name
Levothyroxine Sodium
Generic name
Levothyroxine Sodium
Active ingredient
Levothyroxine Sodium
Route
Oral
NDCs
47781-640, 47781-643, 47781-646, 47781-649, 47781-651, 47781-654, 47781-657, 47781-659, 47781-662, 47781-665 +2 more
FDA application
NDA021116
Affected lot / code info
Lot # HE02221, Exp. 05/2023

Why it was recalled

Sub-Potent Drug: Out of specification for assay at the 24 month interval.

Recalling firm

Firm
Alvogen, Inc
Manufacturer
Alvogen, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
44 Whippany Rd Ste 107, N/A, Morristown, New Jersey 07960-4558

Distribution

Quantity
21,276 bottles
Distribution pattern
Nationwide and Puerto Rico.

Timeline

Recall initiated
2023-02-06
FDA classified
2023-02-24
Posted by FDA
2023-03-08
Terminated
2024-03-18
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0353-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Levothyroxine Sodium · FDA Drug Recalls